A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

被引：0
作者：
Fengchun Zhang
Zhichun Liu
Lindi Jiang
Hao Zhang
Dongbao Zhao
Yang Li
Hejian Zou
Xiaoyue Wang
Xiangpei Li
Bingyin Shi
Jianhua Xu
Hongjie Yang
Shaoxian Hu
Shen Qu
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital
[2] The Second Affiliated Hospital of Soochow University,Department of Rheumatology
[3] Fudan University,Department of Rheumatology, Zhongshan Hospital
[4] The Third Xiangya Hospital of Central South University,Department of Nephrology
[5] Shanghai Changhai Hospital,Department of Rheumatology and Immunology
[6] The Second Affiliated Hospital of Harbin Medical University,Department of Rheumatology and Immunology
[7] Fudan University,Department of Rheumatology, Huashan Hospital
[8] The First People Hospital of Yueyang,Department of Endocrinology
[9] University of Science and Technology of China,Department of Rheumatology and Immunology, The First Affiliated Hospital
[10] The First Affiliated Hospital of Xi’an Jiaotong University,Department of Endocrinology
[11] The First Affiliated Hospital of Anhui Medical University,Department of Rheumatology and Immunology
[12] Shanghai University of Traditional Chinese Medicine,Department of Endocrinology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
[13] Huazhong University of Science and Technology,Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College
[14] Shanghai Tenth People’s Hospital,Department of Endocrinology and Metabolism
来源：
Rheumatology and Therapy | 2019年 / 6卷
关键词：
Febuxostat; Gout; Hyperuricemia; Xanthine oxidase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 98 条
[1]  
Loeb JN(1972)The influence of temperature on the solubility of monosodium urate Arthritis Rheum 15 189-192
[2]  
Roddy E(2014)Epidemiology of gout Rheum Dis Clin North Am 40 155-175
[3]  
Choi HK(2015)Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: a systematic review and meta-analysis Biomed Res Int 2015 762820-3141
[4]  
Liu R(2011)Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008 Arthritis Rheum 63 3136-715
[5]  
Han C(2016)Overview of serum uric acid treatment targets in gout: why less than 6 mg/dl? Postgrad Med 128 706-598
[6]  
Wu D(2007)Relationship between hyperuricemia and metabolic syndrome J Zhejiang Univ Sci B 8 593-452
[7]  
Zhu Y(2011)Clinical practice. Gout N Engl J Med 364 443-234
[8]  
Pandya BJ(1999)Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease Am J Kidney Dis 33 225-194
[9]  
Choi HK(2009)Febuxostat in the treatment of gout: 5-year findings of the FOCUS efficacy and safety study Rheumatology (Oxford) 48 188-1282
[10]  
Ruoff G(2009)Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout J Rheumatol 36 1273-270
12345678910